PCRX catalyst calendar

Pacira BioSciences, Inc.

Upcoming catalysts
4
Cash runway
Cash generating
Cash & investments
$251M
Phase 3 programs
10

Pacira BioSciences, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee on November 15, 2026. There are 4 upcoming events on record.

Pacira BioSciences, Inc. generates cash from operations, so a burn-based runway figure does not apply.

Across 95 concluded trials, 77% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 15, 2026 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee Trial Milestone Phase 2
December 8, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2026 ZILRETTA in Subjects With Shoulder Osteoarthritis Trial Milestone Phase 3
January 15, 2027 Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery Trial Milestone Phase 1

Track PCRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PCRX in the tracker

Recent history

DateEventTypePhase
October 8, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 4, 2026 Quarterly results filed (8-K) Earnings —
June 30, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
June 11, 2026 8-K filed: Leadership change, Other event Corporate —
April 30, 2026 Quarterly results filed (8-K) Earnings —
February 26, 2026 Quarterly results filed (8-K) Earnings —
January 28, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
January 8, 2026 Quarterly results filed (8-K) Earnings —
November 6, 2025 Quarterly results filed (8-K) Earnings —
October 16, 2025 A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip Trial Milestone Phase 2
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 10, 2025 8-K filed: Reg FD disclosure Filing —
July 7, 2025 8-K filed: Material agreement Corporate —
June 13, 2025 8-K filed: Leadership change Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 22, 2025 8-K filed: Other event Filing —
February 27, 2025 Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers Trial Milestone Phase 1
November 28, 2023 Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee Trial Milestone Phase 1
August 17, 2022 Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy Trial Milestone Phase 3
July 11, 2022 Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty Trial Milestone Phase 3
January 11, 2022 Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy Trial Milestone Phase 1
April 5, 2021 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries Trial Milestone Phase 3
December 7, 2020 Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers Trial Milestone Phase 1
August 4, 2020 Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries Trial Milestone Phase 4
June 15, 2020 Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis Trial Milestone Phase 2
January 15, 2020 Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation Trial Milestone Phase 1
January 9, 2020 Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section Trial Milestone Phase 4
December 2, 2019 Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy Trial Milestone Phase 1
November 8, 2019 Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee Trial Milestone Phase 3
October 11, 2019 Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.